Zinc protoporphyrin IX, a heme oxygenase-1 inhibitor, demonstrates potent antitumor effects but is unable to potentiate antitumor effects of chemotherapeutics in mice
2008

Zinc Protoporphyrin IX and Its Antitumor Effects

publication Evidence: moderate

Author Information

Author(s): Nowis Dominika, Bugajski Marek, Winiarska Magdalena, Bil Jacek, Szokalska Angelika, Salwa Pawel, Issat Tadeusz, Was Halina, Jozkowicz Alicja, Dulak Jozef, Stoklosa Tomasz, Golab Jakub

Primary Institution: Medical University of Warsaw

Hypothesis

Can zinc protoporphyrin IX (Zn(II)PPIX), a heme oxygenase-1 inhibitor, enhance the antitumor effects of chemotherapeutics?

Conclusion

Inhibition of HO-1 exerts antitumor effects but should not be used to potentiate antitumor effects of cancer chemotherapeutics unless procedures of selective tumor targeting of HO-1 inhibitors are developed.

Supporting Evidence

  • Zn(II)PPIX induced significant accumulation of reactive oxygen species in tumor cells.
  • Zn(II)PPIX exerted potent cytostatic/cytotoxic effects against human and murine tumor cell lines.
  • Zn(II)PPIX was unable to potentiate antitumor effects of 5-fluorouracil, cisplatin, or doxorubicin in three different tumor models.

Takeaway

Zinc protoporphyrin IX can help fight tumors, but it doesn't make chemotherapy work better.

Methodology

The study used crystal violet staining, clonogenic assays, Western blotting, and flow cytometry to evaluate the effects of Zn(II)PPIX on tumor cells.

Limitations

The study did not explore the timing of Zn(II)PPIX administration in combination with chemotherapeutics.

Participant Demographics

The study involved murine models, specifically BALB/c and C57Bl/6 mice.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1186/1471-2407-8-197

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication